Loading clinical trials...
Loading clinical trials...
The main objective of this study is to evaluate efficacy and safety of (Tamsulosin) HGP0412 and HIP1402 in patients with Benign Prostatic Hyperplasia
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Hanmi Pharmaceutical Company Limited
NCT01747577 · Overactive Bladder, Benign Prostate Hyperplasia, and more
NCT06520267 · Bacteriuria in Symptomatic Benign Prostate Hyperplasia, Antibiotic Susceptibility in Symptomatic Benign Prostate Hyperplasia, and more
NCT02822924 · Benign Prostate Hyperplasia
NCT03831321 · Bladder Cancer, Benign Prostate Hyperplasia, and more
NCT01937871 · Benign Prostate Hyperplasia, Erectile Dysfunction
Hanyang University Guri Hospital
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions